The role of cannabinoid ligands in neurodegenerative diseases: emerging anti-inflammatory, immunomodulation and disease-modifying perspectives.
| Journal | Pharmacological research |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Neurodegenerative diseases (NDs) constitute a growing global health burden driven by population aging and remain without disease-modifying therapies. Although chronic neuroinflammation and aberrant protein aggregation are widely recognized as shared pathological hallmarks of major NDs – including Alzheimer’s, Parkinson’s, Huntington’s diseases and multiple sclerosis – the causal relationships linking immunoinflammatory signaling to neurodegenerative progression remain contentious. Therapeutic strategies targeting neuroinflammation have thus far yielded limited clinical success, underscoring the need for mechanistically grounded and context-specific interventions. The endocannabinoid system (ECS) is a key regulator of synaptic function, glial activity, and immune homeostasis in the central nervous system (CNS), and its dysregulation has been consistently reported in neurodegenerative settings. However, ECS alterations across NDs are heterogeneous and often disease- and stage-dependent,
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What do Alzheimer’s, Parkinson’s, and similar diseases have in common biologically?
Chronic neuroinflammation and abnormal protein aggregation are widely recognized as shared hallmarks of major neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and Huntington’s diseases and multiple sclerosis. However, the summary notes that the causal links between immune and inflammatory signaling and the progression of neurodegeneration remain contentious.
Have treatments targeting brain inflammation worked for neurodegenerative diseases?
So far, with limited success. The summary states that therapeutic strategies targeting neuroinflammation have yielded limited clinical success. It says this underscores the need for interventions that are mechanistically grounded and context-specific.
What role does the endocannabinoid system play in the brain?
The endocannabinoid system is a key regulator of synaptic function, glial activity, and immune balance in the central nervous system. Its dysregulation has been consistently reported in neurodegenerative settings, but these changes are heterogeneous across diseases and often depend on the specific disease and its stage.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
